Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
相关临床试验
16
9 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
9
56.3%
已完成
2
12.5%
招募中
4
25.0%
终止
1
6.3%
暂无批准数据
- The global esophageal cancer market across seven major markets was valued at USD 1.3 billion in 2025 and is projected to grow at a 6% CAGR through 2036, according to a DelveInsight report. - Approximately 79,000 incident cases of esophageal cancer were reported across the 7MM in 2025, with the United States accounting for the largest treatment market share. - Emerging therapies including antibody-drug conjugates such as Telisotuzumab adizutecan, bispecific antibodies like Zanidatamab, and next-generation immunotherapies are expected to reshape the treatment landscape. - Recent FDA approvals of durvalumab, pembrolizumab, and tislelizumab in perioperative and frontline settings have expanded immunotherapy options for esophageal cancer patients.
- Gandeeva Therapeutics and Zymeworks have partnered to apply cryo-EM for high-resolution structural mapping of antibody-antigen interfaces to accelerate drug discovery. - Gandeeva scientists successfully resolved the nine-amino-acid antibody-binding epitope of a small, flexible antigen (<20 kDa) at 2.6 Å resolution, a notably challenging target class. - The structural insights enable more informed antibody lead selection and optimization of biologics, according to Zymeworks CSO Dr. Paul Moore. - Dr. Sriram Subramaniam of Gandeeva described the capability as a "game-changer" for validating both immunization-derived and computationally designed antibodies, including AI-driven candidates.
- CRO acquisitions mid-trial create a 60-90 day high-friction period where TMF completeness can slip from 85-90% to below 70%, directly impacting FDA inspection readiness. - When sponsors are acquired after R&D downsizing, sites face 60-120 days of operational uncertainty with frozen budgets, unanswered invoices, and absent CRA contacts. - ICH E6(R3) and 21 CFR Part 312.52 require documented transfer-of-obligations agreements; sites must demand written confirmation of IND sponsor continuity during any transition. - Vertical integration of MSO and CRO functions under one parent entity raises GCP governance concerns that regulators are increasingly scrutinizing for monitoring independence.
- Oxford BioTherapeutics announced a multi-year strategic collaboration with Bristol Myers Squibb to discover and develop novel T-cell engager therapies for solid tumors using OBT's proprietary OGAP-Verify platform. - The partnership marks OBT's third major pharmaceutical collaboration within 12 months, following strategic agreements with GSK and Roche in 2025, demonstrating strong validation of the OGAP-Verify platform. - Under the agreement, OBT will receive upfront payments and be eligible for milestone payments and royalties, while taking responsibility for discovery through development candidate delivery before BMS leads subsequent activities. - The collaboration leverages OBT's target discovery capabilities with BMS's oncology expertise to advance tumor-selective targets and create differentiated antibody-based therapies for cancer patients.
- Zymeworks will present mature Phase 1 clinical data from ZW191, a folate receptor alpha-targeting ADC with proprietary topoisomerase 1 inhibitor payload, demonstrating potential as a best-in-class therapy for advanced solid tumors. - The company unveiled a novel pan-RAS inhibitor ADC platform featuring multiple candidates (ZW418, ZW427, ZW439) that demonstrate superior potency compared to clinical benchmark RMC-6236 and strong activity across RAS-mutated cancers. - Preclinical data show ZW191's combination potential with standard-of-care agents including carboplatin, paclitaxel, bevacizumab, and PARP inhibitors, driven by enhanced DNA damage in tumor cells. - The pan-RAS ADC platform addresses efficacy and tolerability limitations of current oral RAS inhibitors by delivering targeted therapy with reduced on-target toxicities in normal tissues.
- Pfizer has discontinued development of PF-08052666, an anti-mesothelin antibody-drug conjugate, citing "business strategic reasons" rather than safety concerns. - The decision follows a pattern of mesothelin-targeting therapy failures, including Zymeworks' T-cell engager ZW171, highlighting ongoing challenges with this target. - PF-08052666's discontinuation leaves RemeGen's RC88 as the only clinical-stage mesothelin-targeting ADC currently in development. - The asset, originally developed by MediLink and Harbour BioMed using Tmalin ADC technology, was licensed by Pfizer in December 2023 for $53 million upfront.
- Oxford BioTherapeutics announced a multi-year strategic collaboration with GSK to discover novel antibody-based cancer therapeutics using OBT's proprietary OGAP-Verify platform. - The partnership leverages OBT's enhanced proteomics discovery platform to identify oncology targets with improved drug development attributes for potential first-in-class therapies. - OBT will receive an undisclosed upfront payment plus milestone payments and royalties, marking the company's second major pharma collaboration this year. - The collaboration aims to expand treatment options for cancer patients, as currently only a small fraction are eligible for T-cell engager and antibody-drug conjugate therapies.
- Zymeworks announced a strategic pivot from traditional drug development to a royalty-driven business model, focusing on licensing partnerships and milestone payments rather than commercializing its own medicines. - The decision follows successful late-stage trial results for Ziihera in HER2-positive gastroesophageal adenocarcinoma, positioning the company to receive up to $440 million in milestone payments from partners Jazz Pharmaceuticals and BeOne Medicines. - CEO Kenneth Galbraith stated the new strategy creates more consistent shareholder value and reduces the volatility typically associated with traditional biotech models. - Analysts project Ziihera could generate up to $2.9 billion in peak annual revenue and potentially replace Herceptin across the spectrum of HER2-positive patients.
- Jazz Pharmaceuticals announced positive Phase 3 HERIZON-GEA-01 results showing Ziihera (zanidatamab-hrii) plus chemotherapy significantly improved progression-free survival versus trastuzumab plus chemotherapy in first-line HER2-positive gastroesophageal adenocarcinoma. - The combination of Ziihera plus tislelizumab and chemotherapy demonstrated statistically significant improvements in both overall survival and progression-free survival compared to standard care. - The trial enrolled 914 patients across 300 sites in over 30 countries, marking the first Phase 3 study to show benefit for a novel HER2-targeted therapy over trastuzumab in this indication. - Jazz Pharmaceuticals plans to submit a supplemental Biologics License Application in the first half of 2026 to support Ziihera as first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma.
- Zymeworks Inc. has appointed Dr. Adam Schayowitz as Acting Chief Development Officer to advance the company's broad portfolio of nominated product candidates and strengthen strategic partnerships. - Dr. Schayowitz brings nearly 20 years of oncology drug development experience, having led dozens of global development programs from initiation through approval and commercialization at companies including Pfizer, Tesaro, and Algeta. - The appointment comes at a pivotal moment for Zymeworks as the company advances therapeutic candidates including recent IND clearance for ZW251 and expanded global approvals of zanidatamab for HER2-positive biliary tract cancer. - Zymeworks is rapidly advancing a robust pipeline leveraging expertise in antibody drug conjugates and multispecific antibody therapeutics, with ZW191 Phase 1 study actively recruiting and ZW251 expected to enter clinical trials in 2025.
